GE HealthCare Technologies Inc 美股招股说明书（2025-06-03版本）

SUBJECT TO COMPLETION, DATED JUNE3, 2025 GE HealthCare Technologies Inc.$% Senior Notes due 20$% Senior Notes due 20 We are offering $aggregate principal amount of% senior notes due 20(the “20notes”), and $aggregate principal amount of%senior notes due 20(the “20notes”). The 20notes will bear interest at a rate of% per annum. The 20notes will bear interest at a rate of% perannum. Interest on the 20notes will be payable in cash semi-annually in arrears onandof each year, beginning on, 2025. Interest on We may redeem notes of either series at any time and from time to time, in whole or in part, at the applicable redemption prices and at the times specified under“Description of Notes—Optional Redemption.” If we experience a change of control repurchase event with respect to a series of notes, we may be required to offer to We expect to use the net proceeds from this offering, together with cash on hand, to repay the $1,500million aggregate principal amount outstanding of our5.600% senior notes due 2025 (the “2025 notes”) and pay accrued interest, related premiums, fees, and expenses in connection therewith. Pending the final application of The notes will be our senior unsecured obligations and will rank equally in right of payment with all of our other senior unsecured indebtedness, including ourother outstanding senior notes. The notes will be issued in minimum denominations of $2,000 and in integral multiples of $1,000 in excess thereof. The notes will not be listed on any securities exchange. Investing in the notes involves risks that are described in the “Risk Factors” section of this prospectus supplementbeginning on pageS-5and in our latest Annual Report onForm10-K,which is incorporated by reference into this prospectus Neither the Securities and Exchange Commission (the “SEC”) nor any other regulatory body has approved or disapproved of these securities or passedupon the adequacy or accuracy of this prospectus supplement or the related prospectus. Any representation to the contrary is a criminal offense. The underwriters expect to deliver the notes to purchasers in book-entry form only through the facilities of The Depository Trust Company (“DTC”), including itsparticipants Clearstream Banking S.A. (“Clearstream”) and Euroclear Bank SA/NV (“Euroclear”), against payment in New York, New York on or about, 2025. Joint Book-Running Managers Citigroup J.P. Morgan Table of Contents TABLE OF CONTENTS Prospectus Supplement PageS-iiiS-ivS-vS-vS-1S-5 About this Prospectus SupplementCautionary Statement Concerning Forward-Looking StatementWhere You Can Find More InformationIncorporation of Certain Information by ReferenceSummaryRisk FactorsUse of ProceedsCapitalizationDescription of NotesBook-Entry; Delivery of NotesU.S. Federal Income Tax Considerations toNon-U.S.HoldersUnderwritingLegal MattersExperts Prospectus About this Prospectus Cautionary Statement Concerning Forward-Looking StatementWhere You Can Find More Information Neither we nor the underwriters have authorized any other person to give any information not contained in or incorporated by reference into thisprospectus supplement or the accompanying prospectus or in any free writing prospectus relating to this offering prepared by or on behalf of us or towhich we have referred you. We and the underwriters take no responsibility for, and can provide no assurance as to the reliability of, any otherinformation that others may give you. This prospectus supplement and the accompanying prospectus and any free writing prospectus relating to thisoffering prepared by or on behalf of us or to which we have referred you constitute an offer to sell only the notes offered hereby, but only under Table of Contents It is expected that delivery of the notes will be made against payment therefor on or about, 2025, which is thebusiness day followingthe date of the pricing of the notes. Under Rule15c6-1under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), trades in thesecondary market generally are required to settle in one business day unless the parties to that trade expressly agree otherwise. Accordingly, purchasers Table of Contents ABOUT THIS PROSPECTUS SUPPLEMENT You should rely only on the information contained, or incorporated by reference, in this prospectus supplement and the accompanying prospectus.This document consists of two parts. The first part is this prospectus supplement, which describes the specific terms of this offering. The second part isthe accompanying prospectus, which describes more general information, some of which may not apply to this offering. Neither we nor any underwriterhas authorized anyone to provide you with additional information or information different from that contained in this prospectus supplement and theaccompanying prospectus or in any free writing prospectus filed with the SEC and we take no responsibility for any other information that others maygive you. This prospectus supplem